Identification of a Risk Model for Prognostic and Therapeutic Prediction in Renal Cell Carcinoma Based on Infiltrating M0 Cells

Overview

Journal Sci Rep

Specialty Science

Date 2024 Jun 11

PMID 38862642

Authors

Shiyong Xin

Junjie Su

Ruixin Li

Qiong Cao

Haojie Wang

Zhihao Wei

Chengliang Wang

Chengdong Zhang

Affiliations

Soon will be listed here.

Abstract

The tumor microenvironment (TME) comprises immune-infiltrating cells that are closely linked to tumor development. By screening and analyzing genes associated with tumor-infiltrating M0 cells, we developed a risk model to provide therapeutic and prognostic guidance in clear cell renal cell carcinoma (ccRCC). First, the infiltration abundance of each immune cell type and its correlation with patient prognosis were analyzed. After assessing the potential link between the depth of immune cell infiltration and prognosis, we screened the infiltrating M0 cells to establish a risk model centered on three key genes (TMEN174, LRRC19, and SAA1). The correlation analysis indicated a positive correlation between the risk score and various stages of the tumor immune cycle, including B-cell recruitment. Furthermore, the risk score was positively correlated with CD8 expression and several popular immune checkpoints (ICs) (TIGIT, CTLA4, CD274, LAG3, and PDCD1). Additionally, the high-risk group (HRG) had higher scores for tumor immune dysfunction and exclusion (TIDE) and exclusion than the low-risk group (LRG). Importantly, the risk score was negatively correlated with the immunotherapy-related pathway enrichment scores, and the LRG showed a greater therapeutic benefit than the HRG. Differences in sensitivity to targeted drugs between the HRG and LRG were analyzed. For commonly used targeted drugs in RCC, including axitinib, pazopanib, temsirolimus, and sunitinib, LRG had lower IC50 values, indicating increased sensitivity. Finally, immunohistochemistry results of 66 paraffin-embedded specimens indicated that SAA1 was strongly expressed in the tumor samples and was associated with tumor metastasis, stage, and grade. SAA1 was found to have a significant pro-tumorigenic effect by experimental validation. In summary, these data confirmed that tumor-infiltrating M0 cells play a key role in the prognosis and treatment of patients with ccRCC. This discovery offers new insights and directions for the prognostic prediction and treatment of ccRCC.

Citing Articles

Associations of Sociodemographic Characteristics with Food Choice Motives' Importance Among Mexican Adults: A Cross-Sectional Analysis.

Salas-Garcia M, Bernal-Orozco M, Diaz-Lopez A, Betancourt-Nunez A, Nava-Amante P, Vizmanos B Foods. 2025; 14(2).

PMID: 39856824 PMC: 11764962. DOI: 10.3390/foods14020158.

References

Rosellini M, Marchetti A, Mollica V, Rizzo A, Santoni M, Massari F . Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma. Nat Rev Urol. 2022; 20(3):133-157. DOI: 10.1038/s41585-022-00676-0. View

Pan R, Pan F, Zeng Z, Lei S, Yang Y, Yang Y . A novel immune cell signature for predicting osteosarcoma prognosis and guiding therapy. Front Immunol. 2022; 13:1017120. PMC: 9515362. DOI: 10.3389/fimmu.2022.1017120. View

Sun Y, Rha S, Lee S, Guo J, Ueda T, Qin S . Phase II study of the safety and efficacy of temsirolimus in East Asian patients with advanced renal cell carcinoma. Jpn J Clin Oncol. 2012; 42(9):836-44. DOI: 10.1093/jjco/hys110. View

Sun Z, Tao W, Guo X, Jing C, Zhang M, Wang Z . Construction of a Lactate-Related Prognostic Signature for Predicting Prognosis, Tumor Microenvironment, and Immune Response in Kidney Renal Clear Cell Carcinoma. Front Immunol. 2022; 13:818984. PMC: 8892380. DOI: 10.3389/fimmu.2022.818984. View

Wang P, Sun B, Hao D, Zhang X, Shi T, Ma D . Human TMEM174 that is highly expressed in kidney tissue activates AP-1 and promotes cell proliferation. Biochem Biophys Res Commun. 2010; 394(4):993-9. DOI: 10.1016/j.bbrc.2010.03.109. View

Motzer R, Hutson T, Tomczak P, Michaelson M, Bukowski R, Rixe O . Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007; 356(2):115-24. DOI: 10.1056/NEJMoa065044. View

Gabrusiewicz K, Rodriguez B, Wei J, Hashimoto Y, Healy L, Maiti S . Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype. JCI Insight. 2016; 1(2). PMC: 4784261. DOI: 10.1172/jci.insight.85841. View

Chai L, Dai L, Che Y, Xu J, Liu G, Zhang Z . LRRC19, a novel member of the leucine-rich repeat protein family, activates NF-kappaB and induces expression of proinflammatory cytokines. Biochem Biophys Res Commun. 2009; 388(3):543-8. DOI: 10.1016/j.bbrc.2009.08.043. View

. Checkpoint Inhibitor-TKI Combos Effective in RCC. Cancer Discov. 2019; 9(4):460. DOI: 10.1158/2159-8290.CD-NB2019-024. View

10.

Fu C, Jiang A . Dendritic Cells and CD8 T Cell Immunity in Tumor Microenvironment. Front Immunol. 2019; 9:3059. PMC: 6306491. DOI: 10.3389/fimmu.2018.03059. View

11.

Shiravand Y, Khodadadi F, Kashani S, Hosseini-Fard S, Hosseini S, Sadeghirad H . Immune Checkpoint Inhibitors in Cancer Therapy. Curr Oncol. 2022; 29(5):3044-3060. PMC: 9139602. DOI: 10.3390/curroncol29050247. View

12.

Cui G, Xiao Y . Identification of SAA1 as a prognostic biomarker associated with immune infiltration in glioblastoma. Autoimmunity. 2022; 55(6):418-427. DOI: 10.1080/08916934.2022.2076085. View

13.

Gonzalez-Tablas Pimenta M, Otero A, Arandia Guzman D, Pascual-Argente D, Ruiz Martin L, Sousa-Casasnovas P . Tumor cell and immune cell profiles in primary human glioblastoma: Impact on patient outcome. Brain Pathol. 2020; 31(2):365-380. PMC: 8018082. DOI: 10.1111/bpa.12927. View

14.

Hu J, Yu A, Othmane B, Qiu D, Li H, Li C . Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer. Theranostics. 2021; 11(7):3089-3108. PMC: 7847675. DOI: 10.7150/thno.53649. View

15.

Pucci M, Raimondo S, Urzi O, Moschetti M, Di Bella M, Conigliaro A . Tumor-Derived Small Extracellular Vesicles Induce Pro-Inflammatory Cytokine Expression and PD-L1 Regulation in M0 Macrophages via IL-6/STAT3 and TLR4 Signaling Pathways. Int J Mol Sci. 2021; 22(22). PMC: 8621495. DOI: 10.3390/ijms222212118. View

16.

Zhou Q, Li K, Chen X, He H, Peng S, Peng S . HHLA2 and PD-L1 co-expression predicts poor prognosis in patients with clear cell renal cell carcinoma. J Immunother Cancer. 2020; 8(1). PMC: 7057441. DOI: 10.1136/jitc-2019-000157. View

17.

Getz G, Krishack P, Reardon C . Serum amyloid A and atherosclerosis. Curr Opin Lipidol. 2016; 27(5):531-5. DOI: 10.1097/MOL.0000000000000331. View

18.

Cornu M, Albert V, Hall M . mTOR in aging, metabolism, and cancer. Curr Opin Genet Dev. 2013; 23(1):53-62. DOI: 10.1016/j.gde.2012.12.005. View

19.

Motzer R, Hutson T, Cella D, Reeves J, Hawkins R, Guo J . Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013; 369(8):722-31. DOI: 10.1056/NEJMoa1303989. View

20.

Lambert A, Pattabiraman D, Weinberg R . Emerging Biological Principles of Metastasis. Cell. 2017; 168(4):670-691. PMC: 5308465. DOI: 10.1016/j.cell.2016.11.037. View